Other products
Canigen KC
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by B. bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.
Onset of immunity:
Bordetella bronchiseptica: 72 hours after vaccination;
Canine parainfluenza virus: 3 weeks after vaccination.
Duration of immunity: 1 year
Dose to be administered and administration route
Nasal use.
Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C). Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.
Vaccination scheme:
Dogs should be at least 3 weeks of age. When this vaccine is concurrently administered (i.e. not mixed) with another vaccine in the Canigen range as indicated under section 3.8, dogs should not be younger than the minimum age recommended for the other Canigen vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine agents. In order to get protection for Bordetella bronchiseptica unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section 3.5 Special precautions for use).
Revaccinate annually.
Adverse reactions
Dogs:
|
Very common (>1 animal / 10 animals treated): |
Nasal discharge1. Ocular discharge1. |
|
Common (1 to 10 animals / 100 animals reacted): |
Sneezing1, cough1. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Wheezing1. Lethargy. Vomiting. Hypersensitivity reaction, anaphylactic-type reaction2. Immune mediated haemolytic anaemia, immune mediated thrombocytopenia, immune mediated polyarthritis. |
1 Particularly observed in very young susceptible puppies. Signs are generally mild and transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
2 Such reaction may evolve to a more severe condition, which may be life-threatening. If such reaction occurs appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen KC nasal drops, lyophilisate and solvent for suspension for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 0.4 ml dose of reconstituted vaccine contains:
Active substances:
Bordetella bronchiseptica, strain B-C2, live: 108.0 – 109.7 cfu1
Canine parainfluenza virus, strain Cornell, live: 103.0 – 105.8 TCID502
1colony forming units
2Tissue Culture Infective Dose 50% Excipients:
|
Qualitative composition of excipients and other constituents |
|
Lyophilisate |
|
Hydrolysed gelatin |
|
Sodium chloride |
|
Pancreatic digest of casein |
|
Sorbitol |
|
Disodium phosphate dihydrate |
|
Potassium dihydrogen phosphate |
|
Solvent |
|
Water for injections |
Lyophilisate: off-white or cream-coloured pellet. Solvent: clear colourless solution.
3. CLINICAL INFORMATION
3.1 Target species
Dogs.
3.2 Indications for use for each target species
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by B.
bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.
Onset of immunity: Bordetella bronchiseptica: 72 hours after vaccination;
Canine parainfluenza virus: 3 weeks after vaccination.
Duration of immunity: 1 year
3.3 Contraindications None.
3.4 Special warnings
Vaccinate healthy animals only.
3.5 Special precautions for use
Special precautions for safe use in the target species:
Vaccinated dogs may excrete the Bordetella bronchiseptica vaccine strain up to 6 weeks and the canine parainfluenza vaccine strain up to a few days following vaccination. During this time, the contact of immunosuppressed and unvaccinated dogs with vaccinated dogs should be avoided.
Immunosuppressive medication may impair the development of active immunity and may increase the chance of adverse effects caused by the live vaccine strains. Cats, pigs and unvaccinated dogs may react to the vaccine strains with mild and transient respiratory signs. Other animals, like rabbits and small rodents have not been tested.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Immunocompromised persons are advised to avoid contact with the vaccine and vaccinated animals up to 6 weeks after vaccination. Disinfect hands and equipment after use.
Special precautions for the protection of the environment: Not applicable.
3.6 Adverse events
Dogs:
|
Very common (>1 animal / 10 animals treated): |
Nasal discharge1. Ocular discharge1. |
|
Common (1 to 10 animals / 100 animals reacted): |
Sneezing1, cough1. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Wheezing1. Lethargy. Vomiting. Hypersensitivity reaction, anaphylactic-type reaction2. Immune mediated haemolytic anaemia, immune mediated thrombocytopenia, immune mediated polyarthritis. |
1 Particularly observed in very young susceptible puppies. Signs are generally mild and transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
2 Such reaction may evolve to a more severe condition, which may be life-threatening. If such reaction occurs appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
3.7 Use during pregnancy, lactation or lay
Pregnancy:
Can be used during pregnancy.
3.8 Interaction with other medicinal products and other forms of interaction
Do not administer in conjunction with other intranasal treatments or during antibiotic treatment.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed, with the live vaccines in the Canigen range against canine distemper, canine contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2, where authorised, and inactivated vaccines in the Canigen range against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar
Bananal/Liangguang. In very rare cases a transient acute hypersensitivity reaction may occur when this product is used with other vaccines.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
In case antibiotics are administered within one week after vaccination, the vaccination should be repeated after the antibiotic treatment is finished.
3.9 Administration routes and dosage
Nasal use.
Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C). Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.
Vaccination scheme:
Dogs should be at least 3 weeks of age. When this vaccine is concurrently administered (i.e. not mixed) with another vaccine in the Canigen range as indicated under section 3.8, dogs should not be younger than the minimum age recommended for the other Canigen vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine agents. In order to get protection for Bordetella bronchiseptica unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section 3.5 Special precautions for use).
Revaccinate annually.
3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Particularly in very young puppies, signs of upper respiratory tract disease have been observed after a 10-fold overdose of the vaccine, including ocular and nasal discharges, pharyngitis, sneezing and coughing. The signs started the day after vaccination and have been seen for up to 4 weeks after vaccination.
3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable.
4. IMMUNOLOGICAL INFORMATION
4.1 ATCvet code: QI07AF01
The product contains live Bordetella bronchiseptica strain B-C2 and live canine parainfluenza virus strain Cornell. After intranasal vaccination, the product stimulates the development of active immunity against Bordetella bronchiseptica and canine parainfluenza virus.
No data on the influence of maternal antibodies on the effect of vaccination with this vaccine are available. From literature, it is considered that this type of intranasal vaccine is able to induce an immune response without interference with maternally derived antibodies.
Data are available to show a reduction in shedding of Bordetella bronchiseptica from 3 months to 1 year after vaccination.
5. PHARMACEUTICAL PARTICULARS
5.1 Major incompatibilities
Do not mix with any other veterinary medicinal product, except solvent recommended for use with the veterinary medicinal product.
5.2 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 27 months. Shelf life after reconstitution according to directions: 1 hour.
5.3 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
5.4 Nature and composition of immediate packaging
Lyophilisate:
Type I glass vial of 3 ml (single dose presentation) or 10 ml (5 and 10 dose presentation) closed with a halogenobutyl rubber stopper and aluminium cap.
Solvent:
The solvent supplied for reconstitution is filled in the same type of container as the lyophilisate (Type I glass vial with rubber stopper and aluminium cap). The filling volume is: 1 dose 0.6 ml
5 dose 2.4 ml 10 dose 4.6 ml
Pack sizes:
Cardboard or plastic boxes with 1, 5, 10, 25 or 50 x 1, 5 or 10 doses of vaccine and solvent.
Not all pack sizes may be marketed.
5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
6. NAME OF THE MARKETING AUTHORISATION HOLDER
Intervet International B.V.
7. MARKETING AUTHORISATION NUMBER
Vm 06376/4115
8. DATE OF FIRST AUTHORISATION
29 August 2003
9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS
July 2026
10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT
Veterinary medicinal product subject to prescription.
Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.
Approved 24 July 2026
